CLB — Core Laboratories NV Share Price
0.000.00%
Last trade - 00:00EnergyAdventurousMid CapFalling Star
- $1.21bn
- $1.38bn
- $470.25m
- 92
- 16
- 42
- 50
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 27.2 | ||
| PEG Ratio (f) | 0.61 | ||
| EPS Growth (f) | 79.52% | ||
| Dividend Yield (f) | 0.15% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.48 | ||
| Price to Tang. Book | 22.28 | ||
| Price to Free Cashflow | 58.17 | ||
| Price to Sales | 2.54 | ||
| EV to EBITDA | 27.01 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.85% | ||
| Return on Equity | 6.41% | ||
| Operating Margin | 6.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 647.82 | 700.85 | 668.21 | 487.27 | 470.25 | 510.8 | 581.24 | -4.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +24.86 | -3.43 | +16.94 | n/a | n/a | +80.38 | +78.8 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples. It provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. The Production Enhancement segment includes products and services relating to reservoir well completions, perforations, stimulations and production. It provides integrated diagnostic services to evaluate the effectiveness of well completions. The Reservoir Management segment combines and integrates information from reservoir description and production enhancement services to increase production and recovery of oil and gas from its clients' reservoirs.
Directors
- Lawrence Bruno CSU (61)
- Christopher Hill CFO (51)
- Mark Elvig GCN
- Martha Carnes LED (61)
- Gregory Barnett IND (59)
- Harvey Klingensmith IND (68)
- Michael Straughen IND (71)
- Monique Van Dijken Eeuwijk IND (51)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- July 8th, 1994
- Public Since
- July 10th, 1998
- No. of Shareholders
- 217
- No. of Employees
- 3,700
- Sector
- Oil & Gas Related Equipment and Services
- Industry
- Energy
- Exchange
- New York Stock Exchange
- Shares in Issue
- 46,307,537
- Address
- Van Heuven Goedhartlaan 7 B, AMSTELVEEN, 1181 LE
- Web
- https://www.corelab.com/
- Phone
- +31 204203191
- Auditors
- KPMG LLP
Upcoming Events for CLB
Q3 2022 Core Laboratories NV Earnings Release
Similar to CLB
Antero Midstream
New York Stock Exchange
Archrock
New York Stock Exchange
Ardmore Shipping
New York Stock Exchange
Aris Water Solutions
New York Stock Exchange
Borr Drilling
New York Stock Exchange
FAQ
What is the Core Laboratories NV share price?
As of Today at 07:05 UTC, shares in Core Laboratories NV are trading at $26.15. This share price information is delayed by 15 minutes.
How has the Core Laboratories NV share price performed this year?
Shares in Core Laboratories NV last closed at $26.15 and the price had moved by -31.27% over the past 365 days. In terms of relative price strength the Core Laboratories NV share price has underperformed the S&P500 Index by -27.52% over the past year.
What are the analyst and broker recommendations for Core Laboratories NV?
The overall consensus recommendation for Core Laboratories NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Core Laboratories NV dividend yield?
The Core Laboratories NV dividend yield is 0.15% based on the trailing twelve month period.
Does Core Laboratories NV pay a dividend?
Last year, Core Laboratories NV paid a total dividend of $0.04, and it currently has a trailing dividend yield of 0.15%. We do not have any data on when Core Laboratories NV is to next pay dividends.
When does Core Laboratories NV next pay dividends?
We do not have data on when Core Laboratories NV is to next pay dividends. The historic dividend yield on Core Laboratories NV shares is currently 0.15%.
How do I buy Core Laboratories NV shares?
To buy shares in Core Laboratories NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Core Laboratories NV?
As of the previous close price of $26.15, shares in Core Laboratories NV had a market capitalisation of $1.21bn.
Where are Core Laboratories NV shares listed?
Here are the trading details for Core Laboratories NV:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CLB
What kind of share is Core Laboratories NV?
Based on an overall assessment of its quality, value and momentum Core Laboratories NV is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Core Laboratories NV share price forecast for 2022?
The analyst consensus target price for shares in Core Laboratories NV is $27.83. That is 6.42% above the last closing price of $26.15.
Analysts covering Core Laboratories NV currently have a consensus Earnings Per Share (EPS) forecast of $0.73 for the next financial year.
What is the trend in the Core Laboratories NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Core Laboratories NV. Over the past six months, its share price has outperformed the S&P500 Index by +26.75%.
As of the last closing price of $26.15, shares in Core Laboratories NV were trading -4.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Core Laboratories NV PE Ratio?
The Core Laboratories NV PE ratio based on its reported earnings over the past 12 months is 27.2. The shares last closed at $26.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Core Laboratories NV?
Core Laboratories NV's management team is headed by:
- Lawrence Bruno - CSU
- Christopher Hill - CFO
- Mark Elvig - GCN
- Martha Carnes - LED
- Gregory Barnett - IND
- Harvey Klingensmith - IND
- Michael Straughen - IND
- Monique Van Dijken Eeuwijk - IND